Inventiva shares lead the SBF 120 gainers despite a 14% weekly drop
The Burgundy-based biotech specialising in fibrotic and metabolic diseases rebounds at midday, in a Paris market that is edging higher. The rise places it near the top of the index table, a few days after a sharp decline.
A rebound that recovers only part of the weekly losses
Inventiva shares gain 3.44% to €3.01 during the session, while the SBF 120 rises 0.34% and ranks among the index's strongest performers.
The move softens, without erasing, the 14.12% loss recorded over seven days, and leaves the stock well below its level of three months ago (-23.12%). Over one month, it still shows a gain of 10.05%, achieved during the rebound in October and early November.
Technically, the price remains below its three moving averages: the gap is 8.51% with the MM20 (€3.29) and 3.53% with the MM50 (€3.12), which the stock had regained in early November before losing it again. The support at €2.65 and the resistance at €3.59 frame the current trading range.
Cash runway until end-2027 and revenue expected on November 23
When it published its H1 2026 results on July 29, the company indicated that its cash did not cover operating requirements for the next twelve months, and set its financing horizon at the end of the second quarter of 2027 without additional funding. It recorded no revenue in the first half, compared with €4.5 million a year earlier.
Among the levers cited were the €103 million capital offering and the €75 million financing transaction announced on June 2, as well as the possible exercise of warrants that could bring in up to €116 million.
Inventiva is listed in Paris and on the Nasdaq in the form of ADSs, one security across two markets; the Paris line dominates trading. The next scheduled event is the publication of third-quarter 2026 revenue on November 23.